Farnesyltransferase inhibitors: Potential role in the treatment of cancer

Drugs

Volumn 61, Issue 6, 2001, Pages 723-732

  Cox, A D ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; BMS 241662; CISPLATIN; CP 609754; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPOTHILONE DERIVATIVE; FLUOROURACIL; L 778123; LONAFARNIB; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TAXANE DERIVATIVE; TIPIFARNIB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE MUTATION; HUMAN; MOLECULAR CLONING; MONOTHERAPY; NEUTROPENIA; NONHUMAN; PROTEIN BINDING; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

ANIMALIA;

EID: 0034980637     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161060-00002     Document Type: Review

References (64)

1. The Ras branch of small GTPases: Ras family members don't fall far from the tree
2. Ras oncogenes in human cancer: A review
3. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
4. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells
5. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
6. Protein lipidation in cell signaling
7. Regulation of the mevalonate pathway
8. Farnesyltransferase and geranylgeranyltransferase inhibitors: The saga continues
9. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
10. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
11. Farnesyltransferase inhibitors
12. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
13. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
14. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo
15. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
16. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
17. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
18. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells
19. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment
20. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells
21. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
22. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
23. Promising new developments in cancer chemotherapy
24. BMS-214662, a highly potent apoptotic farnesyltransferase inhibitor
25. Non-Ras targets of farnesyltransferase inhibitors: Focus on Rho
26. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
27. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
28. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors
29. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
30. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice
31. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl: Protein transferase inhibitor
32. Potential molecular targets for manipulating the radiation response
33. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
34. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
35. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
36. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS
37. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
38. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells
39. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents
40. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine
41. Phase-I combination trial of the farnesyltransferase inhibitor (FFI) R115777 with a 5FU/LV regimen in advanced colorectal (CR) or pancreatic (PC) cancer
42. Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule
43. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers
44. A clinical, pharmacodynamic and pharmacokinetic phase I study of SCH 66336 (SCH) an oral inhibitor of the enzyme farnesyl transferase given once daily in patients with solid tumors
45. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
46. Phase I pharmacokinetic trial of the farnesyltransferase inhibitor SCH66336 plus gemcitabine in advanced cancers
47. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
48. Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: Preliminary results of a phase I trial
49. Phase I trial of the farnesyl protein transferase (FPTase) inhibitor L-778123 in combination with radiotherapy
50. Pharmacokinetics (PK) and pharmacodynamics (PD) of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
51. Farnesyltransferase inhibitors: Use of surrogate markers
52. Suppression of mevalonate pathway activities by dietary isoprenoids: Protective roles in cancer and cardiovascular disease
53. Prevention and therapy of cancer by dietary monoterpenes
54. Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer
55. Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells
56. A comparison of the therapeutic and preventive efficacy of a novel Ras farnesyltransferase inhibitor in endogenous mouse carcinogenesis models
57. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors
58. The effects of protein farnesyltransferase inhibitors on trypanosomatids: Inhibition of protein farnesylation and cell growth
59. Protein prenyl transferase activities of Plasmodium falciparum
60. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: Selective inhibition of macrophage localization
61. Protein isoprenylation in suspension-cultured tobacco cells
62. Novel isoprenylated proteins identified by an expression library screen
63. Protein prenylation in spinach chloroplasts
64. Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss